HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aventis/Novartis update

This article was originally published in The Tan Sheet

Executive Summary

No formal negotiations have taken place on price tag for France's number one pharmaceutical company, Aventis CEO Igor Landau says in an April 2 conference call. Landau said the firm has "close to two months" to accelerate price negotiations if Novartis maintains interest; Aventis will propose resolutions including a 2003 dividend to shareholders at a May 19 annual meeting. If the merger is successful, Novartis likely would spin off non-core pharmaceutical and consumer brands into a separate entity (1"The Tan Sheet" March 29, 2004, p. 5)...

You may also be interested in...



Novartis/Aventis Consumer Products Combo Would Be Divested

Novartis would spin-off a combination of its consumer health products and Aventis' older drugs if the two companies were to merge

Neuroscience Challenges Oncology For Top Spot In CDER’s 2019 Novel Approvals

Oncology R&D isn’t waning, but investment in neurology and psychiatry drug development are paying off in new drug approvals. Rapid growth in CDER non-malignant hematology approvals reflects longer, broader trend toward orphan drugs.

In Case You Missed It … News On China Patents, EMA Chief, And More

We clean out your Martin Luther King Day inbox so you don't have to.

Topics

UsernamePublicRestriction

Register

RS127989

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel